NCT02729012View on ClinicalTrials.gov

Effects of Hypertonic Saline Solution (NACL 3%+NAHCO3) on Nasal Inflammation in Children With AR. RinASol- Pilot Study

PHASE4CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions
Allergic Rhinitis
Interventions
DRUG

hypertonic saline solution (NACL 3%+NAHCO3)

Treatment with nebulized hypertonic saline solution (NACL 3%+NAHCO3)

OTHER

Saline Solution (NACL 0,9%)

Treatment with nebulized Saline Solution (NACL 0,9%)

Trial Locations (1)

90146

Institute of Biomedicine and Molecular Immunology (IBIM), National Research Council, Palermo

All Listed Sponsors
lead

Stefania La Grutta, MD

OTHER

NCT02729012 - Effects of Hypertonic Saline Solution (NACL 3%+NAHCO3) on Nasal Inflammation in Children With AR. RinASol- Pilot Study | Biotech Hunter | Biotech Hunter